Biogen Idec's Q1 profit falls on one-time charges and expiring Rituxan royalties
This article was originally published in Scrip
Executive Summary
Biogen Idec's first-quarter income fell by 11% to $217 million owing to one-time charges and the expiry of non-US royalties on the anti-CD20 monoclonal antibody Rituxan (rituximab), which is partnered with Roche. The company also reported only a "modest" increase in the number of patients taking its multiple sclerosis drug Tysabri (natalizumab) during January and February.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.